Members of EAMG suppored the educational activities during the annual meeting of the European Academy of Allergy and Clinical Immunology with several symposia focusing on the potential and benefits of allergen specific immunotherapy. During symposia arranged by members of EAMG the latest products and treatment concepts for administration of allergen vaccines are discussed.

The following symposia were presented at the EAACI meeting:

SUNDAY 12 JUNE

10.30 – 12.00 Company Sponsored Symposium - ALK. Location: Çamlıca

The advancement of allergy immunotherapy - translation from clinical evidence to clinical practice in the 21st century

Chairs : Moises Calderón, United Kingdom & Claus Bachert, Belgium

• Clinical update on allergy immunotherapy – what have we learnt from the "big trials"?
   Ulrich Wahn, Germany

• Allergy immunotherapy tablets – should these be considered “treatment of choice” for grass pollen allergy?
  Moises Calderón, United Kingdom

• Meeting patient expectations – the importance of patient-reported outcomes
  Erkka Valovirta, Finland

• This session will be announced closer to the congress

15.30 – 17.00 Company Sponsored Symposium - Stallergenes. Location: Çamlıca

Grass & mites immunotherapy tablets: consolidating of the new therapeutic class

Chairs : Cezmi Akdis, Switzerland & Linda Cox, United States

• Short term efficacy of the 5-grass SLIT tablet in adult US patients
  Linda Cox, United States

• Sustained effect one year after treatment with the 5-grass pre-coseasonal SLIT tablet
  Sabina Rak, Sweden

• Short term and sustained effect one year after treatment with Dpte/Dfar SLIT tablet in severe non-controlled mites allergic rhinitis patients
  Karl-Christian Bergmann, Germany

• Countering false beliefs in allergen immunotherapy
  Pascal Demoly, France

TUESDAY 14 JUNE

13.30 – 15.00 Company Sponsored Symposium - Allergopharma. Location: Çamlıca

The allergy syndrome and its specific treatment

Chairs : Nikos Papadopoulos, Greece

• Allergy - a chronic systemic disease
  Christian Virchow, Germany

• Subcutaneous immunotherapy - best practice today
  Piotr Kuna, Poland

• Recombinant allergens - the future of SIT
  Randolf Brehler, Germany

The Business Meeting of the Immunotherapy Interest Group is arranged Tuesday 10.30 -12.00

The general programme includes many activities directed towards allergen specific immunotherapy